•
Aptivus (tipranavir)
•
Atripla (efavirenz + emtricitabine
+ tenofovir
•
Epzicom (abacavir + lamivudine)
•
Intelence (etravirine)
•
Kaletra (Lopinavir/ritonavir)
•
Lexiva (fosamprenavir)
•
Prezista (darunavir)
•
Reyataz (atazanavir)
•
Selzentry (maraviroc)
•
Sustiva (efavirenz)
•
Truvada (tenofovir + emtricitabine)
•
Viread (tenofovir)
•
Ziagen (abacavir)
•
Experimental Therapies
•
Women and Children
 Aptivus
(tipranavir) Lack
of a pharmacokinetic effect between steady-state tipranavir/ritonavir
(TPV/r) and single-dose valacyclovir in healthy volunteers
J
Sabo and others. ICAAC/IDSA 2008.
Prezista
(darunavir) Pharmacokinetic
(PK) Evaluation of Darunavir/Ritonavir (DRV/r)
and Raltegravir (RAL) in Healthy Subjects
M Anderson and others. ICAAC/IDSA
2008.
Efficacy
and safety of darunavir/ritonavir 800/100mg
once-daily versus lopinavir/ritonavir in treatment-naïve, HIV-1-infected patients
at 96 weeks: ARTEMIS (TMC114-C211)
A Mills and others. ICAAC/IDSA 2008.
The
Impact of Darunavir/ritonavir (DRV/r) & Raltegravir
(RAL) in the Clinic: A New Era for Treatment-Experienced Patients?
M Mugavero
and others. ICAAC/IDSA 2008.
Pharmacokinetic
interaction between darunavir in combination
with low-dose ritonavir and rifabutin
V Sekar and others. ICAAC/IDSA 2008.
Reyataz
(atazanavir) Atazanavir/Ritonavir
vs Lopinavir/Ritonavir in Antiretroviral-Naïve HIV-1–Infected Patients: CASTLE
96 Week Efficacy and Safety
J Mollina and others. ICAAC/IDSA 2008.
Atazanavir/Ritonavir
(ATV/r) + Abacavir/Lamivudine (ABC/3TC) in Antiretroviral (ART)-Naïve,
HIV-1 Infected, HLA-B*5701 Negative Subjects Demonstrates Efficacy and Safety:
the ARIES Trial
K Squires and others. ICAAC/IDSA 2008. Copyright GlaxoSmithKline.
Used with permission, 2008.
Intelence
(etravirine)
Atripla
(efavirenz + emtricitabine + tenofovir) The
48-Week Effi cacy and Safety of Switching to Fixed-Dose Efavirenz/Emtricitabine/Tenofovir
DF in HIV-1-Infected Patients Receiving HAART
E DeJesus and
others. ICAAC/IDSA 2008. Copyright
GlaxoSmithKline. Used with permission, 2008.
Simplifi
cation of Antiretroviral Therapy with Efavirenz/Emtricitabine/Tenofovir
DF Single Tablet Regimen vs. Continued Unmodifi ed Antiretroviral Therapy
in Virologically-Suppressed, HIV-1-Infected Patients
E DeJesus and others.
ICAAC/IDSA 2008. Copyright GlaxoSmithKline. Used with permission, 2008.
Epzicom
(abacavir + lamivudine)
Long-Term
Efficacy and Safety of Abacavir/Lamivudine
(ABC/3TC) with Fosamprenavir + Ritonavir Versus Lopinavir/Ritonavir (LPV/r) over
144 Weeks
V Estrada and others. ICAAC/IDSA 2008. Copyright
GlaxoSmithKline. Used with permission, 2008.
Characterization
of Virologic Failure Over 96 Weeks by Drug Resistance and Antiviral Response in
ART Naïve Patients Receiving Abacavir/Lamivudine
(ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC) Each with Lopinavir/Ritonavir QD
in the HEAT Study
B
Young and others. ICAAC/IDSA 2008. Copyright
GlaxoSmithKline. Used with permission, 2008.
Atazanavir/Ritonavir
(ATV/r) + Abacavir/Lamivudine (ABC/3TC) in Antiretroviral (ART)-Naïve, HIV-1 Infected,
HLA-B*5701 Negative Subjects Demonstrates Efficacy and Safety: the ARIES Trial
K
Squires and others. ICAAC/IDSA 2008. Copyright
GlaxoSmithKline. Used with permission, 2008.
Limb
and Trunk Fat Changes by Total Body DEXA After 96 Weeks of Treatment with Once
Daily (QD) Fosamprenavir (FPV) Boosted with either 100 mg or 200 mg of Ritonavir
(/r) plus Abacavir (ABC)/Lamivudine(3TC):
COL100758
D Wohl and others. ICAAC/IDSA 2008. Copyright
GlaxoSmithKline. Used with permission, 2008.
Six
Abacavir/Lamivudine (ABC/3TC) Clinical Trials
Show Robust Virologic Responses in ART-Naive Patients for Baseline (BL) Viral
Loads (VL) of .100,000 c/mL and <100,000 c/mL
K
Pappa and others. ICAAC/IDSA 2008. Copyright
GlaxoSmithKline. Used with permission, 2008.
Week
96 Virology Analysis of COL100758, a Study of Once-Daily (QD) Fosamprenavir (FPV)
Boosted with 100 mg or 200 mg Ritonavir (/r) with Abacavir
/Lamivudine (ABC/3TC) in Antiretroviral Naïve HIV-infected Patients
L
Ross and others. ICAAC/IDSA 2008. Copyright GlaxoSmithKline. Used with permission,
2008.
Kaletra
(lopinavir/ritonavir) Single
Agent Therapy with Lopinavir/Ritonavir Suppresses
HIV-1 Viral Replication in ARV Naïve Patients: IMANI II - 96 Week Final Results
J
Gathe and others. ICAAC/IDSA 2008.
Three-year
Efficacy of Lopinavir/ritonavir Monotherapy
in the OK04 Trial
F Pulido and others. ICAAC/IDSA 2008.
Lexiva
(fosamprenavir) Efficacy
and Safety of Fosamprenavir + Ritonavir (FPV/RTV)
700mg/100mg Twice Daily (BID) Versus FPV/RTV 1400mg/100mg Once Daily (QD) with
ABC/3TC QD over 24 Weeks
G. CAROSI and others. ICAAC/IDSA 2008. Copyright
GlaxoSmithKline. Used with permission, 2008.
Limb
and Trunk Fat Changes by Total Body DEXA After 96 Weeks of Treatment with Once
Daily (QD) Fosamprenavir (FPV) Boosted with
either 100 mg or 200 mg of Ritonavir (/r) plus Abacavir (ABC)/Lamivudine(3TC):
COL100758
D Wohl and others. ICAAC/IDSA 2008. Copyright
GlaxoSmithKline. Used with permission, 2008.
Week
96 Virology Analysis of COL100758, a Study of Once-Daily (QD) Fosamprenavir
(FPV) Boosted with 100 mg or 200 mg Ritonavir (/r) with Abacavir /Lamivudine
(ABC/3TC) in Antiretroviral Naïve HIV-infected Patients
L
Ross and others. ICAAC/IDSA 2008. Copyright
GlaxoSmithKline. Used with permission, 2008.
Long-Term
Efficacy and Safety of Abacavir/Lamivudine (ABC/3TC) with Fosamprenavir
+ Ritonavir Versus Lopinavir/Ritonavir (LPV/r) over 144 Weeks
V Estrada
and others. ICAAC/IDSA 2008. Copyright
GlaxoSmithKline. Used with permission, 2008.
Switching
from a 200mg-Ritonavir (RTV, r)-Boosted Fosamprenavir
(FPV) Regimen (700mg/100mg BID or 1400mg/200mg QD) to a 100mg RTV-Boosted FPV
Regimen (1400mg/100mg QD) Yields Similar Efficacy and Safety (the LESS Trial)
G.
Cohen and others. ICAAC/IDSA 2008. Copyright GlaxoSmithKline. Used with permission,
2008.
Selzentry
(maraviroc) Weighted
OBT Susceptibility Score (wOBTSS) is a Stronger Predictor of Virologic Response
at 48 Weeks than Baseline Tropism Result in MOTIVATE 1 and 2
H Valdez and
others. ICAAC/IDSA 2008. Reanalysis
of the MERIT Study with the Enhanced Trofile Assay (MERIT-ES)
M Saag and
others. ICAAC/IDSA 2008.
CD4+
Cell Increases at 48 Weeks in the Maraviroc
Treatment-naive MERIT Trial
A Lazzarin and others. ICAAC/IDSA 2008.Adverse
Event Profile of Maraviroc in Treatment-experienced
Patients Infected with R5 HIV-1
A Ayoub and others. ICAAC/IDSA 2008.
A
Pharmacokinetic Study to Evaluate an Interaction between Maraviroc
and Raltegravir in Healthy Adults
E Andrews and others. ICAAC/IDSA 2008.
Sustiva
(efavirenz) Effect
of Efavirenz on the Pharmacokinetics of Ethinyl
Estradiol and Norgestimate in Healthy Female Subjects
H
Sevinsky and others. ICAAC/IDSA 2008.
Comparison
of Etravirine Resistance and Efavirenz/Nevirapine
Resistance among HIV-1 Infected Patients Who Experienced Virologic Failure with
NNRTI-based Antiretroviral Therapy
S Sungkanuparph and others. ICAAC/IDSA
2008.
Truvada
(tenofovir + emtricitabine)
Characterization
of Virologic Failure Over 96 Weeks by Drug Resistance and Antiviral Response in
ART Naïve Patients Receiving Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine
(TDF/FTC) Each with Lopinavir/Ritonavir QD in the HEAT Study
B
Young and others. ICAAC/IDSA 2008. Copyright GlaxoSmithKline. Used with permission,
2008.
Experimental
Therapies Long-term
Safety of Vicriviroc
L Dunkle and others.
ICAAC/IDSA 2008.
THE
EFFECT OF UGT2B7 INHIBITION ON THE STEADY-STATE PHARMACOKINETICS OF UK-453,061
AFTER MULTIPLE-DOSE ADMINISTRATION IN HEALTHY MALE SUBJECTS
G Langdon and
others. ICAAC/IDSA 2008.
Effect
of etravirine on cytochrome P450 isozymes
assessed by the Cooperstown 5+1 cocktail
M
Scholler-Gyure and others. ICAAC/IDSA 2008.
Viread
(tenofovir) Tenofovir
(TDF)- or Abacavir (ABC)-selected Minority Subpopulations in Viremic
Subjects Detected by Ultra-deep Sequencing
R D’Aquila and others. ICAAC/IDSA
2008.
Ziagen
(abacavir) Tenofovir
(TDF)- or Abacavir (ABC)-selected Minority
Subpopulations in Viremic Subjects Detected by Ultra-deep Sequencing
R
D’Aquila and others. ICAAC/IDSA 2008.
Women
and Children Perceptions
of Care by HIV-Infected Women in the United
States
S Hodder and others. ICAAC/IDSA 2008.
| 
Library
of Slides and Posters